title: MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
abstract: MicroRNAs play critical roles in regulating tumor occurrence and drug sensitivity in ovarian cancers. This study aimed to investigate the key members of MicroRNAs (miRNAs) involved in modulating tumor initiation and drug resistance in primary ovarian cancer cells. An in vitro assay based on tumor clonal formation was established to evaluate tumorigenicity and cisplatin sensitivity. By performing real-time polymerase chain reaction, we examined the expression of nine microRNAs associated with the pathology of ovarian cancers in primary ovarian tumor cells, which were surgically resected from 46 patients with distinct sensitivity to platinum-based chemotherapy. MiR-9, miR-145, and miR-429 were expressed significantly higher in drug-sensitive patients (n = 26) than in drug-resistant ones (n = 20), while higher miR-26a expression was found in resistant patients (p < 0.05). In addition, tumor cells from drug sensitive patients were more tumorigenic than those of drug resistance (p = 0.0013). Cisplatin treatment led to a sharp decrease of clonal formation of drug-sensitive cells but showed slight effects on drug resistant cells. Specific anti-miRs were then employed to downregulate the expression of microRNAs in primary tumor cells. Inhibition of miR-9 resulted in decreased clonal formation and sensitivity to cisplatin, while the knockdown of other three microRNAs did not show any influence in tumorigenesis and drug sensitivity. In conclusion, this study showed that in primary ovarian tumor cells, high expression of miR-9 was associated with enhanced tumorigenesis and increased sensitivity of the tumor cells to cisplatin treatment.
authors.affiliation: Department of Obstetrics and Gynecology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, Heilongjiang, People's Republic of China.
authors.forename: Hong-Min
authors.initials: HM
authors.lastname: Zhao
authors.affiliation: Department of Obstetrics and Gynecology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, Heilongjiang, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.affiliation: Department of Obstetrics and Gynecology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, Heilongjiang, People's Republic of China.
authors.forename: Yu-Hui
authors.initials: YH
authors.lastname: Sun
authors.affiliation: Department of Obstetrics and Gynecology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, Heilongjiang, People's Republic of China.
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Gao
authors.affiliation: Department of Obstetrics and Gynecology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, Heilongjiang, People's Republic of China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Department of Obstetrics and Gynecology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, Heilongjiang, People's Republic of China. zheng_jh06@yeah.net.
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Zheng
mesh_terms: D000328:Adult; D017209:Apoptosis / Q000187:drug effects; D063646:Carcinogenesis / Q000187:drug effects; D000077216:Carcinoma, Ovarian Epithelial; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology
chemical_list: C541874:MIRN92 microRNA, human; D035683:MicroRNAs; D002945:Cisplatin
keywords: Drug resistance; Ovarian cancer; Tumorigenicity; miR-9; microRNA
references.citation: Asian Pac J Cancer Prev. 2014;15(8):3363-8
references.pmid: 24870723
references.citation: Curr Mol Med. 2013 Dec;13(10):1603-12
references.pmid: 24206132
references.citation: Biomed Res Int. 2014;2014:959461
references.pmid: 25101302
references.citation: J Ovarian Res. 2012 Dec 13;5(1):44
references.pmid: 23237306
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Cell Death Dis. 2013 Oct 10;4:e838
references.pmid: 24113172
references.citation: Tumour Biol. 2013 Aug;34(4):2093-8
references.pmid: 23797816
references.citation: Anticancer Res. 2014 Jan;34(1):493-501
references.pmid: 24403507
references.citation: Cancer Res. 2007 Sep 15;67(18):8699-707
references.pmid: 17875710
references.citation: Nat Cell Biol. 2010 Mar;12 (3):209-11
references.pmid: 20173743
references.citation: Nat Cell Biol. 2010 Mar;12 (3):247-56
references.pmid: 20173740
references.citation: Oncogene. 2014 Oct 16;33(42):5017-27
references.pmid: 24141785
references.citation: Biomed Res Int. 2014;2014:249393
references.pmid: 25295252
references.citation: Tumour Biol. 2014 Aug;35(8):7713-7
references.pmid: 24805828
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Gynecol Oncol. 2014 Jun;133(3):640-6
references.pmid: 24713546
references.citation: Neoplasia. 2012 Sep;14(9):868-79
references.pmid: 23019418
references.citation: Yonago Acta Med. 2013 Jun;56(2):43-50
references.pmid: 24031151
references.citation: Int J Cancer. 2014 Sep 15;135(6):1286-96
references.pmid: 24510775
references.citation: Mol Cancer. 2010 Jan 26;9:16
references.pmid: 20102618
references.citation: FEBS J. 2009 Oct;276(19):5537-46
references.pmid: 19702828
references.citation: Brain Pathol. 2009 Jul;19(3):375-83
references.pmid: 18624795
references.citation: Oncol Lett. 2013 Sep;6(3):795-800
references.pmid: 24137413
references.citation: Transl Oncol. 2012 Dec;5(6):469-74
references.pmid: 23397476
references.citation: Front Oncol. 2013 Jun 13;3:153
references.pmid: 23785667
references.citation: Pharmacol Rev. 2012 Jul;64(3):706-21
references.pmid: 22659329
references.citation: Arch Gynecol Obstet. 2013 Aug;288(2):367-74
references.pmid: 23619942
references.citation: Biochem Biophys Res Commun. 2013 Nov 29;441(4):693-700
references.pmid: 24157791